Allogeneic PD-L1 Tumor-targeted High-affinity Natural Killer Cells clinical trials
How each study uses Allogeneic PD-L1 Tumor-targeted High-affinity Natural Killer Cells is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Allogeneic PD-L1 Tumor-targeted High-affinity Natural Killer Cells studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- PD-L1 t-haNK
- 3
Studies by the year they started
3 studies that test it; most in 2019 (1)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2021 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 2
National Cancer Institute (NCI) (1) · ImmunityBio, Inc. (1) · Dana-Farber Cancer Institute (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Allogeneic PD-L1 Tumor-targeted High-affinity Natural Killer Cells.
- Dec 2026PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCCPhase 2 · Dana-Farber Cancer Institute
Studies
Open first, then newest update. How each study uses Allogeneic PD-L1 Tumor-targeted High-affinity Natural Killer Cells is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCCRecruitingPhase 2Dana-Farber Cancer InstituteNCT06239220Written as PD-L1 t-haNK
- Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck CancerCompletedPhase 2National Cancer Institute (NCI)NCT04847466Written as PD-L1 t-haNK
- QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid CancersCompletedPhase 1ImmunityBio, Inc.NCT04050709Written as PD-L1 t-haNK
Given beside what is tested · 3 — Allogeneic PD-L1 Tumor-targeted High-affinity Natural Killer Cells is usual care or a partner of the new treatment
- Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic CancerActive, not recruitingPhase 2ImmunityBio, Inc.NCT04390399Written as PD-L1 t-haNK
- N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive GlioblastomaActive, not recruitingPhase 2ImmunityBio, Inc.NCT06061809Written as PD-L1 t-haNK
- A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior TherapiesTerminatedPhase 1/2ImmunityBio, Inc.NCT04927884Written as PD-L1 t-haNK